{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:51:19Z","timestamp":1786978279394,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Naxitamab is a humanized anti\u2010disialoganglioside (GD2) monoclonal antibody approved for treatment of bone\/bone marrow refractory high\u2010risk neuroblastoma (HR\u2010NB). Compassionate use (CU) expanded access program at Hospital Sant Joan de Deu permitted treatment of patients in complete remission (CR). We here report the survival, toxicity, and relapse pattern of patients in first or second CR treated with naxitamab and sargramostim (GM\u2010CSF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedure<\/jats:title>\n                    <jats:p>\n                      Seventy\u2010three consecutive patients with HR\u2010NB (stage M at age &gt;18\u00a0months or MYCN\u2010amplified stages L1\/L2 at any age) were treated in first or second CR. Treatment comprised five cycles of subcutaneous (SC) GM\u2010CSF for 5\u00a0days at 250\u00a0\u03bcg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day (days \u22124 to 0), followed by naxitamab + SC GM\u2010CSF for 5\u00a0days at 500\u00a0\u03bcg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day (days 1\u20135). Naxitamab was infused over 30\u00a0minutes at 3\u00a0mg\/kg\/day, days 1, 3, and 5, outpatient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty\u2010five patients were in first CR and 18 in second CR. Seventeen patients had MYCN\u2010amplified NB and 11 detectable minimal residual disease in the bone marrow. Fifty\u2010eight (79.5%) patients completed therapy. Four (5%) experienced grade 4 toxicities and 10 (14%) early relapse. Three\u2010year event\u2010free survival (EFS) 58.4%, 95% CI\u00a0=\u00a0(43.5%, 78.4%) and overall survival (OS) 82.4%, 95% CI\u00a0=\u00a0(66.8%, 100%). First CR patients 3\u2010year EFS 74.3%, 95% CI\u00a0=\u00a0(62.7%, 88.1%), and OS 91.6%, 95% CI\u00a0=\u00a0(82.4%, 100%). EFS is significantly different between first and second CR (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.0029). The pattern of relapse is predominantly (75%) of an isolated organ, mainly bone (54%). Univariate Cox models show prior history of relapse as the only statistically significant predictor of EFS but not OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Consolidation with naxitamab and GM\u2010CSF resulted in excellent survival rates for HR\u2010NB patients in CR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pbc.29121","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T12:56:47Z","timestamp":1621688207000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Naxitamab combined with granulocyte\u2010macrophage colony\u2010stimulating factor as consolidation for high\u2010risk neuroblastoma patients in complete remission"],"prefix":"10.1002","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5023-9819","authenticated-orcid":false,"given":"Jaume","family":"Mora","sequence":"first","affiliation":[{"name":"Pediatric Cancer Center Barcelona Hospital Sant Joan de D\u00e9u  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Center Barcelona Hospital Sant Joan de D\u00e9u  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Gorostegui","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Center Barcelona Hospital Sant Joan de D\u00e9u  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Santa\u2010Mar\u00eda","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Center Barcelona Hospital Sant Joan de D\u00e9u  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Garraus","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Center Barcelona Hospital Sant Joan de D\u00e9u  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Center Barcelona Hospital Sant Joan de D\u00e9u  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Varo","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Center Barcelona Hospital Sant Joan de D\u00e9u  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Perez\u2010Jaume","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Center Barcelona Hospital Sant Joan de D\u00e9u  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Ma\u00f1e","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Center Barcelona Hospital Sant Joan de D\u00e9u  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70291-6"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70069-X"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8925"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70309-7"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11642"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.011"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357900601130763"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3909"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30578-3"},{"issue":"6","key":"e_1_2_9_12_1","first-page":"2642","article-title":"Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells","volume":"45","author":"Cheung NK","year":"1985","journal-title":"Cancer Res"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.3807"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19864"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01467-4"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.0177"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-014-1273-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_9_19_1","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch JD","year":"1980"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-9473(98)00096-6"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1016704"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28687"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.122"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.144"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.03.013"},{"key":"e_1_2_9_26_1","first-page":"567","article-title":"Stage IV neuroblastoma more than 1 year of age at diagnosis: major response to chemotherapy and survival durations correlated strongly with dose intensity","volume":"366","author":"Cheung NK","year":"1991","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2003.11.028"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30934"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26192"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6393"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.575009"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712590802715764"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4005"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01892"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2014.986459"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061264"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29121","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:56:19Z","timestamp":1692989779000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/pbc.29121"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29121","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"2021-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29121"}}